You have 1 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD27 expressing Solid Tumors

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumors Trial in Beijing (HX009)

Active, not recruiting
  • Advanced Solid Tumors
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciense
Feb 7, 2023

Advanced Solid Tumor Trial in Beijing (KM257 Bispecific antibody)

Not yet recruiting
  • Advanced Solid Tumor
  • KM257 Bispecific antibody
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Apr 8, 2022

Malignant Solid Tumor Trial (GEN1042, Pembrolizumab, Cisplatin)

Not yet recruiting
  • Malignant Solid Tumor
  • GEN1042
  • +4 more
  • (no location specified)
Sep 21, 2023

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

Recurrent or Metastatic Solid Tumors Trial (Recombinant Anti-EpCAM-CD3 Antibody Injection)

Not yet recruiting
  • Recurrent or Metastatic Solid Tumors
  • Recombinant Anti-EpCAM-CD3 Antibody Injection
  • (no location specified)
Oct 17, 2023

Epithelial Ovarian Cancer, Triple Negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer Trial in Paris, Rennes, Milano

Recruiting
  • Epithelial Ovarian Cancer
  • +2 more
  • NI-1801
  • Paris, France
  • +4 more
Nov 4, 2022

Advanced Solid Tumor, NSCLC, Small Cell Lung Cancer Trial (IMM2520)

Not yet recruiting
  • Advanced Solid Tumor
  • +5 more
  • (no location specified)
Mar 20, 2023

Advanced Solid Tumor Trial (ES014)

Withdrawn
  • Advanced Solid Tumor
  • (no location specified)
Jan 30, 2023

Breast Cancer Trial in Shanghai (A166)

Recruiting
  • Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 6, 2022

Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma Trial in Zhengzhou (CD70 CAR-T cells)

Recruiting
  • Metastatic Tumor
  • +4 more
  • CD70 CAR-T cells
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 19, 2022

Tumor Malignant Trial in Worldwide (SAR443216)

Recruiting
  • Neoplasm Malignant
  • Houston, Texas
  • +7 more
Jul 13, 2022

Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous

Active, not recruiting
  • Recurrent Head and Neck Squamous Cell Carcinoma
  • +3 more
  • 200 mg Pembrolizumab
  • +2 more
  • Miami, Florida
  • +6 more
Jan 9, 2023

Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma Trial in Jinan (CD70 CAR-T cells)

Recruiting
  • Metastatic Tumor
  • +4 more
  • CD70 CAR-T cells
  • Jinan, Shandong, China
    The Second People's Hospital of Shandong Province
Jun 14, 2022

Advanced/Metastatic Solid Tumors Trial in Kurralta Park, Clayton (ADG206)

Not yet recruiting
  • Advanced/Metastatic Solid Tumors
  • Kurralta Park, South Australia, Australia
  • +1 more
Nov 9, 2022

Non Small Cell Lung Cancer, Solid Tumor Trial in Jette, Brussel (Avelumab, Ipilimumab 5 MG/ML, Pembrolizumab 100 MG in 4 ML

Recruiting
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • Jette, Brussels, Belgium
  • +1 more
Sep 9, 2022

Advanced Solid Tumors Trial in Tianjin (SKB315 for injection)

Recruiting
  • Advanced Solid Tumors
  • SKB315 for injection
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
May 10, 2022

Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma Trial in Nashville (CTX131)

Recruiting
  • Clear Cell Renal Cell Carcinoma
  • +4 more
  • CTX131
  • Nashville, Tennessee
    Research Site 1
Mar 21, 2023

Solid Tumor, Adult Trial in Boston, Canton, Houston (HB0045 Drug Product)

Not yet recruiting
  • Solid Tumor, Adult
  • HB0045 Drug Product
  • Boston, Massachusetts
  • +2 more
Sep 20, 2023

Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3) Trial in New York, Cincinnati (Codrituzumab)

Recruiting
  • Primary Extra-cranial Solid Tumor
  • Recurrent or Refractory Glypican 3 (GPC3)
  • Los Angeles, California
  • +2 more
Oct 28, 2022

Advanced Solid Tumors Trial in Guangdong (JS019)

Recruiting
  • Advanced Solid Tumors
  • JS019
  • Guangdong, Guangzhou, China
    Guangdong General Hospital
Aug 17, 2022

Solid Tumor, Adult Trial in Boston, Canton, Houston (HB0045 Drug Product)

Not yet recruiting
  • Solid Tumor, Adult
  • HB0045 Drug Product
  • Boston, Massachusetts
  • +2 more
Jul 5, 2023

HER2 Positive Solid Tumors Trial in Australia, Korea, Republic of, United States (SBT6050, pembrolizumab, Cemiplimab)

Active, not recruiting
  • HER2 Positive Solid Tumors
  • Boston, Massachusetts
  • +11 more
Jun 27, 2022

Solid Tumors Trial in Kashiwa, Nishinomiya, Chuo-ku (TAK-103)

Recruiting
  • Solid Tumors
  • TAK-103
  • Kashiwa, Chiba, Japan
  • +2 more
Mar 10, 2022

Solid Tumor Trial in Suzhou (68Ga-NODAGA-SNA006)

Recruiting
  • Solid Tumor
  • 68Ga-NODAGA-SNA006
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 8, 2022

Germ Cell Tumor, Nonseminomatous Germ Cell Tumor Trial in Chapel Hill (ATLCAR.CD30 Cells, Cyclophosphamid, Fludarabine)

Recruiting
  • Germ Cell Tumor
  • Nonseminomatous Germ Cell Tumor
  • ATLCAR.CD30 Cells
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Dec 13, 2022